ImmuPharma plc (LON:IMM – Get Free Report) rose 27.6% on Saturday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.35 ($0.04). Approximately 8,992,934 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 23,308,711 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Price Performance
The firm has a market cap of £13.95 million, a price-to-earnings ratio of -335.00 and a beta of 1.53. The business has a 50-day moving average of GBX 1.59 and a 200-day moving average of GBX 1.69.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- What is the Hang Seng index?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- What Are Dividend Achievers? An Introduction
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
